Welcome to our dedicated page for Theratechnologies news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies stock.
Theratechnologies Inc (NASDAQ: THTX) is a specialty biopharmaceutical company advancing therapies for HIV complications and oncology conditions. This news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access timely information about FDA-approved HIV treatments like EGRIFTA for lipodystrophy and Trogarzo for multidrug-resistant infections, alongside emerging oncology candidates targeting aggressive cancers. Our curated news collection includes earnings reports, partnership announcements, and research breakthroughs.
Key updates cover three focus areas: commercialized HIV therapies, pipeline progress in oncology, and operational developments across North American/European markets. Content types include clinical trial results, regulatory filings, and executive commentary.
Bookmark this page for structured access to Theratechnologies' latest advancements in niche biopharmaceutical solutions. Verify information directly through company filings and press releases for informed decision-making.
Theratechnologies has announced an agreement with Canadian underwriters to sell 14,546,000 units at US$2.75 per unit, raising approximately US$40 million. Each unit comprises one common share and one-half warrant, with a three-year exercise price of US$3.18. The offering's net proceeds will mainly support research and development, commercialization, and general corporate needs. Closing is expected around January 19, 2021, subject to regulatory approvals, including Toronto Stock Exchange listing.
Theratechnologies (THTX) expects record revenues for Q4 and FY 2020, estimating between $18.9 million and $19.2 million for Q4, a rise of 15% to 17%, and $65.8 million to $66.1 million for FY 2020, up 4.1% to 4.6%. The company received FDA approval for Phase 3 trials of tesamorelin in NASH and Phase 1 trials for TH1902 in various cancers. The Phase 3 trial for tesamorelin aims to enroll 2,000 participants and is set to start in Q3 2021, while the TH1902 trial is planned to initiate in Q2 2021.
Theratechnologies (NASDAQ: THTX) has announced promising pre-clinical findings for TH1902, a novel peptide-drug conjugate targeting SORT1+ cancers. New results show TH1902's efficacy in colorectal, pancreatic, melanoma, and endometrial cancers, building on earlier findings in ovarian and triple-negative breast cancers. Importantly, toxicity studies confirm TH1902 can be administered at three times the maximum tolerated dose of docetaxel, suggesting a potentially improved safety profile. These findings herald a significant step forward for treatments targeting hard-to-treat cancers.
MONTREAL, Nov. 23, 2020 – Theratechnologies (TSX: TH, NASDAQ: THTX) announced participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1-2, 2020. Paul Levesque, President and CEO, will be featured in a pre-recorded fireside chat available for online viewing. Interested parties can access the chat via the company's website. Theratechnologies is dedicated to developing innovative therapies for unmet medical needs. For more details, visit www.theratech.com.
Theratechnologies (THTX) presented new data at The Liver Meeting® 2020, highlighting significant serum protein reductions linked to Nonalcoholic Steatohepatitis (NASH) in patients treated with tesamorelin. Results showed a reduction in Vascular Endothelial Growth Factor A (VEGFA), Transforming Growth Factor Beta 1 (TGFβ1), and Colony Stimulating Factor 1 (CSF1) levels, suggesting potential therapeutic benefits for NASH treatment. These findings build on previous liver biopsy analyses, reinforcing tesamorelin's role in addressing liver fat and fibrosis issues.
Theratechnologies (NASDAQ: THTX) announced that Dr. Lindsay T. Fourman will present data on tesamorelin and its effects on nonalcoholic fatty liver disease (NAFLD) at The Liver Meeting 2020, hosted by the American Association for the Study of Liver Diseases (AASLD), from November 13-16. The presentation titled "Treatment with Growth Hormone Releasing Hormone Analog Reduces VEGFA, TGFβ1, and CSF1" is scheduled for November 16 at 9:00 AM. This highlights a significant step in understanding the therapeutic effects of tesamorelin.
Theratechnologies (THTX) announced the resignation of Jovan Antunovic, Senior VP and Chief Commercial Officer, effective November 13, 2020. His departure comes after nearly two years with the company, where he enhanced their sales and marketing in the U.S. Paul Lévesque, CEO, will temporarily oversee operations until a new candidate is recruited. The company is focusing on finding someone with extensive U.S. experience to continue driving growth.
MONTREAL, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (THTX) announced participation in several upcoming virtual investor conferences. Management will be at B. Riley Securities' Liver Disease Therapeutics Day on October 29, 2020, featuring a panel with Dr. Christian Marsolais. Additionally, Paul Levesque will present at the 29th Annual Credit Suisse Healthcare Conference on November 10, 2020, at 8:45 a.m. ET. Webcast details will be available on the company's website one day prior to each event.
Theratechnologies has appointed Andrew Molson and Alain Trudeau as new independent members of its Board of Directors. This strategic move aims to enhance the board's expertise as the company progresses in developing tesamorelin for Nonalcoholic Steatohepatitis (NASH) and advancing its SORT1+ Technology in oncology. Ms. Dawn Svoronos, the Chair of the Board, expressed confidence in their contributions as the firm seeks to strengthen its market position.
Theratechnologies (THTX) reported financial results for Q3 FY2020, with revenues of $14,049,000, a slight decrease from $16,111,000 in Q3 FY2019. Key highlights include advancing tesamorelin for NASH treatment, restructuring sales strategies, and transitioning to EGRIFTA SV®. Despite COVID-19 challenges, the company expects to submit a Phase 3 protocol for tesamorelin to regulatory agencies soon. The net loss was $6,768,000 or $(0.09) per share compared to a loss of $1,639,000 or $(0.02) per share in Q3 FY2019.
